SavedAdd your journal

Journals / Türk Kardiyoloji Derneği Arşivi / 2020 / Cilt: 48 - Sayı: 7

The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: A multicenter retrospective cohort study

COVID-19 hastalarında CHA2DS2-VASc skoru ve hastane içi mortalite: Çok merkezli geriye dönük kohort çalışması

Samir ALLAHVERDİYEV
Alaa QUİSİ
Hazar HARBALIOĞLU
Gökhan ALICI
Ömer GENÇ
Abdullah YILDIRIM
İbrahim Halil KURT
Fahri ER
Pages
656–663
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mortality outcomeswere followed up until April 25, 2020.Results: The CHA2DS2-VASc score was significantlyhigher in non-survivor COVID-19 patients than in survivorCOVID-19 patients (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Coronavirus disease 2019 (COVID-19) is an infectiousdisease that was first reported in December 2019in Wuhan, China, and has since spread rapidly around theworld, resulting in the ongoing COVID-19 pandemic.
📊
Key Findings & Data:TheCHA2DS2-VASc score is a well‐validated risk stratificationtool for predicting stroke in atrial fibrillation (AFib), as wellas morbidity and mortality in several entities.
💡
Conclusion & Impact:Mortality outcomeswere followed up until April 25, 2020.Results: The CHA2DS2-VASc score was significantlyhigher in non-survivor COVID-19 patients than in survivorCOVID-19 patients (p
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Coronavirus disease 2019 (COVID-19) is an infectiousdisease that was first reported in December 2019in Wuhan, China, and has since spread rapidly around theworld, resulting in the ongoing COVID-19 pandemic. TheCHA2DS2-VASc score is a well‐validated risk stratificationtool for predicting stroke in atrial fibrillation (AFib), as wellas morbidity and mortality in several entities. The aim ofthis study was to evaluate the relationship between theCHA2DS2-VASc score and in-hospital mortality in patientswith COVID-19, regardless of AFib.Methods: This multicenter, retrospective study included atotal of 349 patients with COVID-19 who were hospitalizedbetween March 15 and April 15, 2020. The CHA2DS2-VAScscore of each patient was calculated. Mortality outcomeswere followed up until April 25, 2020.Results: The CHA2DS2-VASc score was significantlyhigher in non-survivor COVID-19 patients than in survivorCOVID-19 patients (p

Özet

Amaç: Koronavirus hastalığı 2019 (COVID-19), ilk kez Aralık 2019’da Çin’in Wuhan kentinde bildirilen ve o zamandan beri dünya çapında hızla yayılan ve devam eden pandemiye neden olan bulaşıcı bir hastalıktır. CHA2DS2-VASc skoru, atriyal fibrilasyonda inmenin yanı sıra çeşitli durumlarda morbidite ve mortaliteyi tahmin etmek için iyi doğrulanmış bir risk sınıflandırma skorudur. Bu çalışmada, COVID-19 hastalarında CHA2DS2-VASc skoru ile hastane içi mortalite arasındaki ilişkiyi değerlendirmeyi amaçladık. Yöntemler: Bu çok merkezli retrospektif çalışmaya 15 Mart ile 15 Nisan 2020 tarihleri arasında hastaneye yatırılan toplam 349 COVID-19 hastası dahil edildi. Her hastanın CHA2DS2-VASc skoru hesaplandı. Ölüm sonuçları 25 Nisan 2020’ye kadar takip edildi. Bulgular: Hayatta kalmayan COVID-19 hastalarında CHA2DS2-VASc skorları hayatta kalanlara göre anlamlı olarak yüksekti (p

🔖

Cite This Article

ALLAHVERDİYEV, S., QUİSİ, A., HARBALIOĞLU, H., ALICI, G., GENÇ, Ö., YILDIRIM, A., KURT, İ. H., ER, F. (2022). The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: A multicenter retrospective cohort study. Türk Kardiyoloji Derneği Arşivi, Cilt: 48 - Sayı: 7, 656–663. https://ajindex.com/articles/632399

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al
  2. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020
  3. 727−33. [CrossRef] 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020
  4. 497−506. [CrossRef] 3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020
  5. 507−13. [CrossRef] 4. Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation 2020
  6. 1903−14. 5. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. Int J Cardiol 2020
  7. 116−21. [CrossRef] 6. Ammirati E, Wang DW. SARS-CoV-2 inflames the heart. The importance of awareness of myocardial injury in COVID-19 inpatients. Int J Cardiol 2020
  8. 122−3. [CrossRef] 7. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020
  9. 1003−8. 8. Mishra AK, Sahu KK, Lal A, Sargent J. Patterns of heart injury in COVID-19 and relation to outcome. J Med Virol. 2020 Apr 8. doi: 10.1002/jmv.25847. [Epub ahead of print]. [CrossRef] 9. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020
  10. 145−7. [CrossRef] 10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020
  11. 1061−9. [CrossRef] 11. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the euro heart survey on atrial fibrillation. Chest 2010
  12. 263−72. [CrossRef] 12. Saliba W, Gronich N, Barnett-Griness O, Rennert G. Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study. Am J Med 2016
  13. 843−9. [CrossRef] 13. Huang FY, Huang BT, Pu XB, Yang Y, Chen SJ, Xia TL, et al. CHADS2, CHA2DS2-V